Stay updated on Y90-Radioembolization Plus Nivolumab in Asian HCC Clinical Trial

Sign up to get notified when there's something new on the Y90-Radioembolization Plus Nivolumab in Asian HCC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Y90-Radioembolization Plus Nivolumab in Asian HCC Clinical Trial page

  1. Check
    7 days ago
    Change Detected
    Summary
    The update shows minor UI adjustments and a refreshed last-updated date, with no changes to core study information such as eligibility, interventions, outcomes, or participating sites. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2025-11-03T01:12:13.000Z thumbnail image
  2. Check
    14 days ago
    No Change Detected
  3. Check
    36 days ago
    Change Detected
    Summary
    Update includes a critical operating status notice and a new software version (v3.2.0), indicating updated deployment with potential service impact; previous version reference (v3.1.0) was removed.
    Difference
    3%
    Check dated 2025-10-05T09:14:50.000Z thumbnail image
  4. Check
    43 days ago
    Change Detected
    Summary
    Version updated from v3.0.2 to v3.1.0.
    Difference
    0.1%
    Check dated 2025-09-28T03:06:20.000Z thumbnail image
  5. Check
    57 days ago
    Change Detected
    Summary
    The page revision is updated from v3.0.1 to v3.0.2, signaling an update; the Back to Top element was removed.
    Difference
    0.2%
    Check dated 2025-09-13T16:42:37.000Z thumbnail image
  6. Check
    64 days ago
    Change Detected
    Summary
    The web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes in core content, names, pricing, or availability.
    Difference
    0.2%
    Check dated 2025-09-06T14:06:27.000Z thumbnail image
  7. Check
    72 days ago
    Change Detected
    Summary
    The web page has undergone significant updates, including the addition of new facility names and various types of proteins and antibodies, while removing several terms related to antineoplastic agents and specific location details.
    Difference
    3%
    Check dated 2025-08-30T11:05:31.000Z thumbnail image

Stay in the know with updates to Y90-Radioembolization Plus Nivolumab in Asian HCC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Y90-Radioembolization Plus Nivolumab in Asian HCC Clinical Trial page.